Evaluation of the Bioequivalence of Two Faropenem Formulations in Healthy Indian Subjects

This paper presents the results of a two-period, two-treatment, crossover study conducted in 12 Indian male volunteers under fasting conditions to assess the bioequivalence of two oral formulations (Reference and Test) containing 200 mg of faropenem (CAS 106560-14-9). Both of the formulations were administered orally as a single dose separated by a washout period of 1 week. The content of faropenem in plasma was determined by a validated HPLC method with UV detection. The formulations were compared using the parameters area under the plasma concentration-time curve (AUC0-t), area under the plasma concentration-time curve from zero to infinity (AUC0-infinity), peak plasma concentration (Cmax) and time to reach peak plasma concentration (tmax). The results Indicated that there were no statistically significant differences between the logarithmically transformed AUC0-infinity and Cmax values between the test and reference formulation. The 90% confidence interval for the ratio of the logarithmically transformed AUC0-t, AUC0-infinity and Cmax were within the bioequivalence limit of 0.8-1.25 and the relative bioavailability of the test formulation was 97.74% of that of the reference formulation.